Direct access to fully audited GLP/non-GLP study packages, from active extraction and chromatographic fingerprinting to high-tier animal toxicokinetics and human clinical trial supply.
Across international markets, chemical safety dossiers have transformed from routine compliance checkmarks into decisive commercial gatekeepers. Global regulatory agencies—including the United States FDA, the European Medicines Agency (EMA), the European Chemicals Agency (ECHA under REACH), and the Chinese NMPA—demand rigorous quantitative toxicological profiling before complex plant matrices can enter high-value consumer sectors.
Global harmonization requires botanical chemical characterization to meet exact OECD Test Guidelines (such as OECD 471 Ames, OECD 487 Micronucleus, and OECD 408 90-Day Oral Rodent toxicity). Pharmaceutical authorities will no longer accept ambiguous traditional usage narratives without validated chemical exposure limits (PDE/TDI) and metabolic stability studies.
The enactment of the US Modernization of Cosmetics Regulation Act (MoCRA) and EU Regulation (EC) No 1223/2009 has mandated Cosmetic Product Safety Reports (CPSR) with calculated Margins of Safety (MoS). Unstandardized plant extracts lacking quantitative systemic toxicity values (NOAEL) face widespread port rejections and clinical bans.
Under US FDA 21 CFR Part 190.6 (New Dietary Ingredient Notifications) and EFSA Novel Food regulations, historical consumption alone is insufficient for non-standardized concentrated extracts. A definitive toxicological profile detailing residual solvents, heavy metals, pesticide clearance, and genotoxic absence is obligatory.
Toxicological profiling is experiencing a paradigm shift from empirical animal lethality tests toward mechanistic toxicology, New Approach Methodologies (NAMs), and predictive artificial intelligence algorithms that unravel botanical synergy.
| Assessment Parameter | Legacy Testing Framework | Modern Regulatory Standard (GLP) | Next-Gen MedGence Pipeline (NAMs/AI) |
|---|---|---|---|
| Acute Toxicity Assessment | Crude LD50 in high-volume rodents | OECD 423 / OECD 425 Acute Toxic Class method | In Silico QSAR Toxicity Estimation Software Tool (T.E.S.T.) + In Vitro Neutral Red Uptake (3T3 NRU) |
| Genotoxic Carcinogenicity | Single Ames test, unvalidated batching | GLP Tier 1 Battery: OECD 471 (Ames) + OECD 487 (In Vitro Micronucleus) | High-throughput GreenScreen HC assay + High-Content Imaging for DNA double-strand breaks |
| Repeat-Dose Target Organ Toxicity | General necropsy without mechanistic bio-markers | OECD 407 (28-day) / OECD 408 (90-day oral) with full histopathology | Multi-organ microphysiological systems (Organ-on-a-Chip) coupled with targeted transcriptomics |
| Metabolic Bioactivation | Uncharacterized in vivo liver metabolism | In vitro Cytochrome P450 (CYP450) inhibition and induction assays | Cryopreserved human hepatocyte 3D spheroids + LC-MS/MS reactive metabolite profiling |
| Botanical Variability Control | Single chemical marker HPLC quantification | Multivariate HPLC/HPTLC fingerprinting + chemical fingerprint consistency | Chemical-toxicological correlation mapping across geography, seasonal harvest, and plant morphology |
With the FDA Modernization Act 2.0 and global cosmetic animal testing prohibitions, chemical suppliers must provide certified NAMs. MedGence integrates human primary cell assays and reconstructive epidermis models (SkinEthic/EpiDerm) to ensure international acceptance.
Botanicals are complex multi-constituent mixtures. Synergistic toxicity, where harmless single isolates become toxic when co-administered, requires comprehensive botanical active screening and quantitative fingerprint validation across seasons and regional cultivars.
We leverage computational toxicogenomics to forecast reactive pathways, endocrine disruption, and receptor binding before wet-lab validation begins, decreasing evaluation timelines by up to 60% while elevating data precision for institutional stakeholders.
Delivering tailored non-clinical toxicology reports designed to resolve jurisdictional bottlenecks across diverse multinational industries.
The Challenge: Proving safety of high-potency standardized botanical extracts without historical GRAS status.
Our Turnkey Solution: We execute subchronic 90-day rodent oral toxicity, reproductive toxicity screening (OECD 421/422), and calculate undisputed Acceptable Daily Intake (ADI) and No Observed Adverse Effect Levels (NOAEL) for seamless FDA NDI filings.
The Challenge: Meeting strict CDER/FDA or EMA investigational new drug (IND) criteria for botanical drugs.
Our Turnkey Solution: Full Phase 1 to Phase 4 clinical trial design, safety pharmacology batteries (hERG cardiotoxicity, CNS, respiratory), and extensive pharmacokinetic/toxicokinetic profiling supporting new drug applications (NDAs).
The Challenge: Achieving global cosmetics inventory clearance without animal testing data.
Our Turnkey Solution: In vitro human skin irritation (OECD 439), phototoxicity (OECD 432 3T3 NRU PT), ocular corrosion (BCOP/OECD 437), and Direct Peptide Reactivity Assays (DPRA/OECD 442C) for skin sensitization verification.
The Challenge: Establishing rigorous reproducible quality and pharmacological safety for complex ancient formulas.
Our Turnkey Solution: Translating historical empirical TCM experience into verified modern chemical datasets, having modernized 83 classic formulations and 56 hospital preparations with full quality dossiers.
MedGence (Yineng Pharma) operates as an elite contract research and contract development manufacturing organization based in Changsha, Hunan, China. We bridge raw agricultural sourcing with audited global market approval.
Sourcing variation directly impacts toxicity and potency. We analyze natural botanical materials harvested across diverse geographical origins, seasonal windows, and plant anatomical parts (roots, stems, leaves, inflorescences) to establish optimal extraction parameters and chemical thresholds.
Reproducibility is paramount. Our analytical laboratories establish validated High-Performance Thin-Layer Chromatography (HPTLC), High-Performance Liquid Chromatography (HPLC), and Gas Chromatography (GC) methods to ensure active assay quantification and total absence of adulterants.
From laboratory pilot scale to fully commercial batch release. Our facilities supply active raw materials as concentrated liquids, spray-dried powders, pastes, and volatile essential oils, or complete finished dosage units: oral liquids, softgels, hard capsules, tablets, and granular sachets.
Direct technical and commercial answers addressing non-clinical study design, regulatory submissions, pilot-to-commercial CDMO production, and botanical safety profiles.
Engage our specialized multidisciplinary scientific teams for discrete analytical packages, in vitro/in vivo toxicological testing, or end-to-end pharmaceutical development.
